Amarin (AMRN) Gets Intention to Grant Patent in Europe for AMR101

July 25, 2012 7:27 AM EDT Send to a Friend
Amarin Corporation plc (Nasdaq: AMRN), reports that the European Patent Office has issued an intention to grant letter for European Patent Application Number EP2395991, titled "Use of Eicosapentaenoic Acid Ethyl Ester for Treating Hypertriglyceridemia." This patent application is intended to protect the exclusivity of Amarin's drug candidate, AMR101, for use in an indication that Amarin may seek through the European Medicines Agency (EMA).

"This European intention to grant letter further substantiates that the findings from Amarin's MARINE clinical trial were unexpected and follows the recent issuance of a pharmaceutical composition patent in the United States (U.S. Patent No. 8,188,146) covering EPA with no DHA in a capsule and Notice of Allowance for U.S. Patent Application Serial Number 12/769,885 titled "Highly Stable EPA in a Capsule," stated Joseph Zakrzewski, Chairman and Chief Executive Officer of Amarin. "This patent application is part of Amarin's expanding patent portfolio intended to cover AMR101. Amarin is currently prosecuting greater than 25 pending U.S. patent applications and multiple other patent applications outside the United States with the goal of protecting the commercial potential of AMR101 to 2030 and beyond."


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA

Add Your Comment